Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Covid-19 vaccination prevents 39,700 hospitalisations and 13,200 deaths: PHE

Public Health England estimates that the coronavirus vaccination programme has prevented about 39,700 hospitalisations and 13,200 in people aged 60 years or older up to the middle of May.

The method for analysing the approximate number of deaths and hospitalisations prevented by the vaccine programme now takes into account the impact of both first and second doses, due to more data being available.


However, it does not include the impact of vaccination on transmission, therefore the true impact of the vaccination programme is likely to be even greater.

An updated analysis including nearly 3,000 symptomatic cases of B.1.617.2 provides further confidence that 2 doses of either vaccine are highly effective against the variant first identified in India.

Dr Jamie Lopez Bernal, consultant epidemiologist at PHE, said: “This analysis gives further confidence that 2 doses of the vaccine provide vital protection against the variants in circulation in the UK, so it is important to book your second jab when invited to gain maximum protection.

“The vaccines are very safe and very effective, and they will protect you and those around you from becoming seriously ill.”

More For You

Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less